



**m eloma**  
new zealand



**HSANZ**

Haematology Society of  
Australia and New Zealand

# Myeloma Summit

24-26 August 2018

**m eloma**  
new zealand



# HANDBOOK

St Moritz Hotel | Queenstown | 24 - 26 August 2018



# Welcome

Dear Industry Colleague

I would like to welcome you all to the Second International Myeloma Summit Meeting in the resort town of Queenstown. The meeting is jointly hosted by HSANZ and Myeloma New Zealand. It will commence on the Friday evening with welcome drinks and nibbles and will be followed by a talk from Karen Nimmo who is a well known psychologist. She has personal experience of being involved in a blood cancer journey and will share her insights of the experience.

We have an exciting programme planned over the week- end and this will be spear headed by our Canadian keynote speaker who is Professor Donna Reece from Toronto. We are also pleased to welcome back Ola Landgren from New York who will deliver a talk over the internet.

Dr Hang Quach from Melbourne will be presenting an Australian perspective and we have our local talent to round out the programme.

The conference dinner will be at Sherwood on Saturday evening and the food promises to be of a high standard. The meeting will conclude at Sunday midday.

We look forward to welcoming you to this meeting which promises much.

Ken Romeril  
Convenor, CEO Myeloma NZ

**St Moritz Hotel | Queenstown | 24 - 26 August 2018**



## Friday Night Speaker - Karen Nimmo

Karen Nimmo is a clinical psychologist and writer based in Wellington, New Zealand. She specialises in resilience, mind-body health and peak performance for sports and business.

Karen is a regular media commentator on psychological topics. She writes a blog and is the author of two books: *My Bum Looks Brilliant In This* (the one true secret of lasting weight loss) and *Fish Pie Is Worse Than Cancer*, the story of her own family's experience with cancer.

[www.onthecouch.co.nz](http://www.onthecouch.co.nz)



## Keynote Speaker - Dr Donna Reece

Dr. Donna Reece is Professor and Director of the Program for Multiple Myeloma and Related Diseases in the Department of Medical Oncology and Hematology at Princess Margaret Cancer Centre/University of Toronto. She was awarded the David and Molly Bloom Chair in Multiple Myeloma Research in 2009.

Dr. Reece graduated with honors from Baylor College of Medicine in Houston, Texas and completed her training in Hematology/Oncology at Barnes Hospital, Washington University, St. Louis, Missouri. Dr. Reece is currently the co-chair of the Multiple Myeloma Subcommittee of the Canadian Cancer Trials Group (CCTG), member of the Scientific Advisory Board of the International Myeloma Foundation, and member of the Project Review Committee of the Multiple Myeloma Research Consortium (MMRC). She currently serves on the Board of Directors of Myeloma Canada and has spearheaded the development of the Myeloma Canada Research Network (MCRN). She has conducted many clinical trials and published numerous articles in the area of hematopoietic stem cell transplantation and plasma cell disorders.



## Keynote Speaker - A/Prof. Hang Quach

A/Prof. Hang Quach is the director of clinical haematology research at St. Vincent's Hospital and principal fellow of the University of Melbourne. She currently serves as co-chair of the ALLG Myeloma Disease Group, member of the Research Advisory Group of the Australian Myeloma Research Consortium (AMaRC), as well as councilor of the Specialist Medical Review Council on multiple myeloma, to the Australian Minister of Veterans' Affairs. Dr Quach is a member of the Medical Scientific Advisory Group (MSAG) to Myeloma Australia, and leads the development and bi-annual update of the Australian Myeloma National Treatment Guideline. Her translational and clinical research focuses on novel therapeutics and the immunology of multiple myeloma, from which she has published over 50 peer-reviewed manuscripts and attracted grants/scholarships totaling over 4.5 million dollars towards research in multiple myeloma.



## Keynote Speaker - Professor Ola Landgren

I am a board-certified hematologist-oncologist whose research focuses on the development of novel treatment strategies and advanced disease monitoring by new minimal residual disease (MRD) assays, as well as biological studies focusing on disease and host biology.

I also study mechanism and markers of progression from MGUS/smoldering myeloma to symptomatic multiple myeloma, and the identification of high-risk precursor patients who may be candidates for early treatment. I have a strong interest in the development of early-treatment clinical trials targeting high-risk smoldering myeloma.

I am one of the pioneers in the development of MRD testing in myeloma. In collaboration with colleagues at MSK as well nationally/internationally, I develop new strategies (including cell-based, molecular-based, and imaging-based) and implement advanced MRD testing in clinical trials at MSK.

## Friday 24th August

6pm  
7pm

Welcome Function

Karen Nimmo – “On the Couch”

*Karen Nimmo is a clinical psychologist and writer based in Wellington, New Zealand. She specialises in resilience, mind-body health and peak performance for sports and business. Karen is a regular media commentator on psychological topics.*

Free evening for dinner

## Saturday 25th August

8.30 – 8.40

Dr Ken Romeril: Welcome.

### Session One:

8.40 – 9.20

Chair – Dr Peter Ganley

Prof Hang Quach – *Real world outcome for patients with MM in Australia and New Zealand: how to optimize treatment based on what we have learnt*

9.20 – 9.45

Dr Dirk Hoenemann – *The IMiD Story Continues*

9.45 – 10.05

Dr Ken Romeril – *CyBORd 5 year Results*

10.05 – 10.30

Dr Philip George – *Car-T cell therapy*

10.30 – 11.00

Morning Tea

### Session Two:

11.00 – 11.45

Chair – Dr Henry Chan

Prof Donna Reece – *High Risk Multiple Myeloma*

11.45 – 12.10

Dr Anup George – *Bone therapy in Myeloma*

12.10 – 12.30

Dr David Simpson – *t (11:14) Myeloma*

12.30 – 1.30

Lunch

### Session Three:

1.30 – 1.55

Chair – Dr Anup George

Dr Remy Lim – *Myeloma Imaging*

1.55 – 2.20

Dr Colin Hutchison – *Myeloma Kidney*

2.20 – 3.00

Prof Donna Reece – *Treatment of Relapsed/Refractory patients*

3.00 – 3:20

Afternoon tea

### Session Four:

3.20 – 3.30

Chair – Dr David Simpson

Myeloma NZ – *Barbara Horne*

3.30 – 3.55

Dr Hugh Goodman – *Amyloid*

3.55 – 4.15

Dr Richard Milne – *Burden of Disease Report*

4.15 – 5.00

Panel discussion – *Myeloma therapy in NZ - future prospects*

7pm

Dinner held at Sherwood.

Bus will depart at 6.45pm to take you there and return you to St Moritz after dinner.

## Sunday 26th August

### Session Five:

8:30 – 8.50

Chair – Dr Ken Romeril

Dr Henry Chan – *CyBORd in the Elderly*

8:50 – 9.10

Prof Ian Morison – *Otago Myeloma Research Unit, roxithromycin and more*

9:10 – 9.30

Dr Peter Ganly – *Tandem auto transplants*

9.30 – 10.15

Professor Ola Landgren – *Should we use MRD to guide our treatment of myeloma?*

10.15 – 10.45

Morning Tea

### Session Six:

10.45 – 12.30

Panel Discussion – *Nursing care and symptom control*

12.30

Closing Comments



# Platinum Sponsors



## Committed to Improving the Lives of Patients Worldwide

Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialisation of products for the treatment of cancer and other severe, immune, inflammatory conditions.

“At Celgene, we seek to deliver truly innovative and life-changing drugs for patients.”

Globally, there are more than 300 clinical trials at major medical centres using compounds from Celgene. Investigational compounds are being studied for patients with incurable haematological and solid tumour cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukaemia (CLL), non-Hodgkin's lymphoma (NHL), small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so.

### Contact details

Kirsty Vercoe  
New Zealand Area Manager, Celgene Limited  
Suite 120, Plaza Level, 41 Shortland Street, Auckland 1010, New Zealand.  
M: +64 27 535 5688, Office: 0800 526 529, E: kvercoe@celgene.com



At Janssen, we collaborate with the world for the health of everyone in it. What matters most to us is a healthy outcome for each patient. We're committed to providing safe and effective medicines as well as the services and support that contribute to healthy outcomes. Now the fastest growing of the top 10 pharmaceutical companies globally, we're focusing our unique model of innovation on some of the most devastating diseases and the most complex medical challenges of our time, across five therapeutic areas; Immunology, Oncology, Neuroscience, Cardiovascular Medicine, and Infectious Disease.

Products include Velcade for myeloma and Ribomustin for indolent Non-Hodgkins Lymphoma.

### Contact details

Lisa Gilliver  
507 Mt Wellington Highway, Mt Wellington, Auckland 1060, New Zealand  
PO Box 62185, Sylvia Park, Auckland 1644

St Moritz Hotel | Queenstown | 24 - 26 August 2018



# Bronze Sponsors



## Oncology

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

### Contact details

Anthony Caton  
Email: [medinfo.JAPAC@amgen.com](mailto:medinfo.JAPAC@amgen.com)



Our mission is to discover new ways to improve and extend people's lives.

We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

### Contact details

Zoe Mullaghan, Business Manager  
Oncology | Haematology, Novartis New Zealand Limited  
Ground Floor, 109 Carlton Gore Road, Newmarket, Auckland 1023  
Office: +64 9 523 8500, Fax: +64 9 3618181, Mobile: +64 21750224, Toll Free: 0800 838 909  
Email: [zoe.mullaghan@novartis.com](mailto:zoe.mullaghan@novartis.com)



Sanofi is dedicated to supporting people through their health challenges.

We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide self-care solutions to better manage personal wellbeing and provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe."


### Contact details

Sanofi  
56 Cawley Street, Ellerslie, Auckland 1051  
Phone 0800 283684, website: [www.sanofi.com.au](http://www.sanofi.com.au)

St Moritz Hotel | Queenstown | 24 - 26 August 2018



# Notes



**St Moritz Hotel | Queenstown | 24 - 26 August 2018**




# MYELOMA SUMMIT

Thanks to our Sponsors  
Platinum



Bronze



St Moritz Hotel | Queenstown | 24 - 26 August 2018